DOPTELETの薬剤に関する洞察と市場予測：2032年

DOPTELETはトロンボポエチン受容体作動薬で、これまでの治療で十分な効果が得られなかった慢性ITPの成人患者における血小板減少症の治療に適応があります。

慢性ITPに伴う血小板減少症については、米国で承認されています。EUでは、ヒト用医薬品委員会（CHMP）が、他の治療に抵抗性の成人患者における原発性慢性ITPに対して肯定的意見を採択しています。また、ドナー造血幹細胞移植後のITPおよび血小板減少症の小児患者を対象に評価中です。

アバトロンボパグは、経口で生物学的に利用可能な低分子のTPO受容体作動薬であり、骨髄前駆細胞からの巨核球の増殖および分化を刺激し、血小板の産生を増加させます。アバトロンボパグはTPO受容体への結合においてTPOと競合せず、血小板に対するTPOとの相加効果を有します。

当レポートでは、主要7ヶ国におけるDOPTELET市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 免疫性血小板減少症 （ITP）に対するDOPTELETの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 DOPTELET市場評価

• ITPに対するDOPTELETの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるITPに対するDOPTELETの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: DOPTELET, Clinical Trial Description, 2023
• Table 2: DOPTELET, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: DOPTELET Market Size in the 7MM, in USD million (2019-2032)
• Table 6: DOPTELET Market Size in the US, in USD million (2019-2032)
• Table 7: DOPTELET Market Size in Germany, in USD million (2019-2032)
• Table 8: DOPTELET Market Size in France, in USD million (2019-2032)
• Table 9: DOPTELET Market Size in Italy, in USD million (2019-2032)
• Table 10: DOPTELET Market Size in Spain, in USD million (2019-2032)
• Table 11: DOPTELET Market Size in the UK, in USD million (2019-2032)
• Table 12: DOPTELET Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: DOPTELET Market Size in the 7MM, USD million (2019-2032)
• Figure 2: DOPTELET Market Size in the United States, USD million (2019-2032)
• Figure 3: DOPTELET Market Size in Germany, USD million (2019-2032)
• Figure 4: DOPTELET Market Size in France, USD million (2019-2032)
• Figure 5: DOPTELET Market Size in Italy, USD million (2019-2032)
• Figure 6: DOPTELET Market Size in Spain, USD million (2019-2032)
• Figure 7: DOPTELET Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: DOPTELET Market Size in Japan, USD million (2019-2032)

“"DOPTELET Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about DOPTELET for immune thrombocytopenic purpura (ITP) in the seven major markets. A detailed picture of the DOPTELET for ITP in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DOPTELET for ITP. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DOPTELET market forecast analysis for ITP in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ITP.

Drug Summary:

DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to previous treatment.

For thrombocytopenia with chronic ITP, it is approved in the US. In the EU, Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for primary chronic ITP in adult patients who are refractory to other treatments.

It is also being evaluated in pediatric subjects with ITP and thrombocytopenia after donor hematopoietic stem cell transplant.

Dosage

Chronic ITP: Initiate DOPTELET at 20 mg (one tablet) once daily. Adjust the dose or frequency of dosing to maintain a platelet count greater than or equal to 50 × 109/L. Do not exceed 40 mg per day.

Mechanism of action

Avatrombopag is an orally bioavailable, small-molecule TPO receptor agonist that stimulates the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DOPTELET description, mechanism of action, dosage and administration, research and development activities in immune thrombocytopenic purpura (ITP).
• Elaborated details on DOPTELET regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DOPTELET research and development activities in ITP across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DOPTELET.
• The report contains forecasted sales of DOPTELET for ITP till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ITP.
• The report also features the SWOT analysis with analyst views for DOPTELET in ITP.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DOPTELET Analytical Perspective by DelveInsight

In-depth DOPTELET Market Assessment

This report provides a detailed market assessment of DOPTELET for immune thrombocytopenic purpura (ITP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

DOPTELET Clinical Assessment

The report provides the clinical trials information of DOPTELET for ITP covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for immune thrombocytopenic purpura (ITP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DOPTELET dominance.
• Other emerging products for ITP are expected to give tough market competition to DOPTELET and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DOPTELET in ITP.
• Our in-depth analysis of the forecasted sales data of DOPTELET from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DOPTELET in ITP.

Key Questions:

• What is the product type, route of administration and mechanism of action of DOPTELET?
• What is the clinical trial status of the study related to DOPTELET in immune thrombocytopenic purpura (ITP) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DOPTELET development?
• What are the key designations that have been granted to DOPTELET for ITP?
• What is the forecasted market scenario of DOPTELET for ITP?
• What are the forecasted sales of DOPTELET in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to DOPTELET for ITP?
• Which are the late-stage emerging therapies under development for the treatment of ITP?

Table of Contents

1. Report Introduction

2. DOPTELET Overview in ITP

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DOPTELET Market Assessment

• 5.1. Market Outlook of DOPTELET in ITP
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DOPTELET in the 7MM for ITP
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DOPTELET in the United States for ITP
  • 5.3.2. Market Size of DOPTELET in Germany for ITP
  • 5.3.3. Market Size of DOPTELET in France for ITP
  • 5.3.4. Market Size of DOPTELET in Italy for ITP
  • 5.3.5. Market Size of DOPTELET in Spain for ITP
  • 5.3.6. Market Size of DOPTELET in the United Kingdom for ITP
  • 5.3.7. Market Size of DOPTELET in Japan for ITP

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options